FULC

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.

Wall Street analysts forecast FULC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FULC is 14.50 USD with a low forecast of 6.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Fulcrum Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Fulcrum Therapeutics Inc. EPS for the last quarter amounts to -0.31 USD, decreased -11.43 % YoY.

Fulcrum Therapeutics Inc (FULC) has 45 emplpoyees as of December 15 2025.

Today FULC has the market capitalization of 857.61M USD.